Steven Roczniak

Title: Innovations of Steven Roczniak

Introduction

Steven Roczniak is a notable inventor based in Lafayette, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of interleukin-4 muteins. With a total of 2 patents to his name, Roczniak's work has the potential to impact therapeutic approaches in medicine.

Latest Patents

Roczniak's latest patents include innovations related to DNA encoding high affinity interleukin-4 muteins. One of his patents describes a recombinant human IL-4 mutein that features at least one amino acid substitution in the binding surface of either the A- or C-alpha helices of the wild-type IL-4. This mutein binds to the IL-4Rα receptor with greater affinity than native IL-4. The preferred substitution at position 13 is Thr to Asp. Additionally, his work encompasses pharmaceutical compositions, amino acid and polynucleotide sequences encoding the muteins, transformed host cells, antibodies to the muteins, and methods of treatment. Another patent focuses on high-affinity interleukin-4 muteins that also include substitutions at specific positions, enhancing their binding capabilities.

Career Highlights

Roczniak is currently associated with Bayer Corporation, where he continues to advance his research and development efforts. His work is pivotal in the field of immunology and therapeutic development.

Collaborations

Some of his notable coworkers include Jeffrey M Greve and Armen B Shanafelt, who contribute to the collaborative efforts in their research endeavors.

Conclusion

Steven Roczniak's innovative work in the field of biotechnology, particularly with interleukin-4 muteins, showcases his commitment to advancing medical science. His contributions have the potential to lead to significant advancements in therapeutic treatments.